Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05983783 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

Name: Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC — clinical trial record (NCT05983783)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorThe First Affiliated Hospital with Nanjing Medical University

Started2023-08-01

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 9, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

The First Affiliated Hospital with Nanjing Medical University

275 trials monitored

See 6 trials at risk

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

Evaluate whether the combination of Rezvilutamide and androgen deprivation therapy (ADT) with docetaxel improves overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to the combination of Rezvilutamide and ADT.

Trial Details

NCT Number	NCT05983783
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemotherapy Effect
Enrollment	200 participants
Start Date	2023-08-01
Primary Completion	2025-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2023-08-09